158 related articles for article (PubMed ID: 32124472)
1. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Rouette J; Yin H; Yu OHY; Bouganim N; Platt RW; Azoulay L
Diabet Med; 2020 May; 37(5):868-875. PubMed ID: 32124472
[TBL] [Abstract][Full Text] [Related]
2. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety trials of incretin-based drugs: What do they mean?
Yabe D; Seino Y
J Diabetes Investig; 2017 May; 8(3):272-276. PubMed ID: 27612317
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract][Full Text] [Related]
5. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.
Wilhite K; Reid JM; Lane M
Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914
[TBL] [Abstract][Full Text] [Related]
6. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Engström A; Wintzell V; Melbye M; Svanström H; Eliasson B; Gudbjörnsdottir S; Hveem K; Jonasson C; Hviid A; Ueda P; Pasternak B
Hepatology; 2024 Jun; 79(6):1401-1411. PubMed ID: 38085855
[TBL] [Abstract][Full Text] [Related]
7. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
Pradhan R; Yu OHY; Platt RW; Azoulay L
Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
Lin Y; Xu G; Li L; Xiang J; Zhai L
Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
[TBL] [Abstract][Full Text] [Related]
9. Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.
Igweokpala S; Sule NO; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2024 Feb; 26(2):721-731. PubMed ID: 38031234
[TBL] [Abstract][Full Text] [Related]
10. New prospects for incretin-related drugs in the treatment of type 2 diabetes.
Kimura T; Kaku K
J Diabetes Investig; 2021 Jul; 12(7):1141-1143. PubMed ID: 33151639
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ
Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic perturbations in humans as a tool to generate mechanistic insight.
Florez JC
Diabetes; 2013 Sep; 62(9):3019-21. PubMed ID: 23970522
[No Abstract] [Full Text] [Related]
13. Case report: GLP1RA for the treatment of diabetes in liver transplanted people. Do they increase the risk of pancreatitis?
Grancini V; Cogliati I; Gaglio A; Resi V; Orsi E
Front Endocrinol (Lausanne); 2024; 15():1392371. PubMed ID: 38779453
[TBL] [Abstract][Full Text] [Related]
14. Duration of Type 2 Diabetes and Incidence of Cancer: An Observational Study in England.
Zaccardi F; Ling S; Brown K; Davies M; Khunti K
Diabetes Care; 2023 Nov; 46(11):1923-1930. PubMed ID: 37639691
[TBL] [Abstract][Full Text] [Related]
15. Improving Outcomes of Chronic Obstructive Pulmonary Disease through the Treatment of Comorbidities: One Step Beyond.
Miravitlles M
Am J Respir Crit Care Med; 2023 Nov; 208(10):1017-1019. PubMed ID: 37672750
[No Abstract] [Full Text] [Related]
16. Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes.
Santella C; Yin H; Hicks BM; Yu OHY; Bouganim N; Azoulay L
Epidemiology; 2020 Jul; 31(4):559-566. PubMed ID: 32282437
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Lin WQ; Cai ZJ; Chen T; Liu MB; Li N; Zheng B
Front Endocrinol (Lausanne); 2021; 12():684960. PubMed ID: 34484112
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of empagliflozin on hematocrit levels in a patient with severe anemia.
Budzianowski J; Rzeźniczak J; Hiczkiewicz J; Kasprzak D; Winnicka-Zielińska A; Musielak B; Pieszko K; Burchardt P
Daru; 2021 Dec; 29(2):507-510. PubMed ID: 34545553
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Frías JP; Maaske J; Suchower L; Johansson L; Hockings PD; Iqbal N; Wilding JPH
Diabetes Obes Metab; 2022 Jan; 24(1):61-71. PubMed ID: 34514692
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
